FDMT Stock Earnings 4D Molecular Therapeutics Beats EPS, Misses Revenue for Q1 2024
FDMT Stock | USD 7.79 0.20 2.50% |
Slightly above 66% of 4D Molecular's investor base is looking to short. The analysis of the overall investor sentiment regarding 4D Molecular Therapeutics suggests that many traders are alarmed. 4D Molecular's investing sentiment can be driven by a variety of factors including economic data, 4D Molecular's earnings reports, geopolitical events, and overall market trends.
FDMT |
FDMT stock results show that 4D Molecular Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Read at investorplace.com
4D Molecular Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards 4D Molecular can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
4D Molecular Fundamental Analysis
We analyze 4D Molecular's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 4D Molecular using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 4D Molecular based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
4D Molecular is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
4D Molecular Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with 4D Molecular stock to make a market-neutral strategy. Peer analysis of 4D Molecular could also be used in its relative valuation, which is a method of valuing 4D Molecular by comparing valuation metrics with similar companies.
Peers
4D Molecular Related Equities
REPL | Replimune | 35.11 | ||||
GOSS | Gossamer Bio | 6.06 | ||||
CCCC | C4 Therapeutics | 5.99 | ||||
LYRA | Lyra Therapeutics | 5.56 | ||||
MLYS | Mineralys Therapeutics, | 5.22 | ||||
AKRO | Akero Therapeutics | 4.90 | ||||
BDTX | Black Diamond | 4.53 | ||||
NVCT | Nuvectis Pharma | 4.08 | ||||
KRON | Kronos Bio | 3.45 | ||||
CGEM | Cullinan Oncology | 2.62 | ||||
STOK | Stoke Therapeutics | 1.42 | ||||
BMEA | Biomea Fusion | 0.94 | ||||
EWTX | Edgewise Therapeutics | 0.69 | ||||
RVMD | Revolution Medicines | 0.05 | ||||
IPSC | Century Therapeutics | 2.42 | ||||
PASG | Passage Bio | 5.56 |
Additional Tools for FDMT Stock Analysis
When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.